Wednesday, April 6, 2011
8:45 am Chairperson’s Remarks & Recap of Previous Day
Donna M. Shaw, Ph.D., CLP, Assistant Director, Life Science Licensing, UC San Diego Technology Transfer Office
9:00 Licensing Deals Gone Bad and How to Best Rectify Them
Irina Erenburg, Ph.D., Director, Strategic Transactions, Research Ventures and Licensing Partners Healthcare System
How do big and small companies look at contracts? How do companies deal with expenses that weren’t anticipated? Can signing a license be a barrier to entry? How are milestones and royalty rates set? Should a reimbursement risk be included in the deal structure? Is a VC financed deal better than a pharma financed deal? How can licensing be used as a non-funding mechanism? What do you do when you and your partner no longer have shared objectives? Thought leaders and attendees will explore these questions as well as criteria for not killing a deal.
9:30 Networking Coffee Break in Exhibit Area
10:00 Panel Discussion: Tell Us What You Don’t Like About Your Partnership
Anne Altmeyer, Ph.D., MBA, MPH, Executive Director, Business Development & Licensing, Oncology, Novartis Pharmaceuticals Corporation
Nick Dunscombe, Senior Executive Director and Head of Alliance Management Center of Excellence, AstraZeneca
Ailsa Mendez-Fitzwilliam, Director, Project Governance, Functional Genetics, Inc. (Moderator)
Personality of deal makers and people with poor interactive skills impact a deal’s demise or success. Thought leaders and attendees will share best practices in deal execution and communication. Additionally, we’ll discuss other execution situations including how to handle small companies who want to be involved in clinical trial design and fostering open communication to keep the deal from falling apart.
11:00 Case Study Presentation: The Partnering Survival Manual - Lessons Learned and Tips to Get Your Alliance Off to a Good Start
Alessandro Foti, MBA, PMP, Head, Program Management, Hydra Biosciences, Inc.
While the terms “alliance” and “partnership” may suggest otherwise, parties in an alliance are usually not equal in status, and never in nature. Starting at due diligence, navigating towards success requires steering around the expectations, attitudes, processes and motivations of two very different groups, and only careful consideration of the needs, cultures and hidden agendas of the parties involved can lead to positive results. Observations, experience and lessons learned from a typical “alliance of unequals,” will be shared.
11:30 am Close of Biopharma Licensing Congress
12:00 – 2:00 pm Workshop: Project Management Keys to Driving Successful Alliances: Key Learnings from Alliance Projects*
(*separate registration required. Boxed lunch provided. 2 PDUs provided.)
Day 1 | Day 2